Predictive Value of Atrial Electromechanical Delay on Long-Term Cardiovascular Outcomes in Hemodialysis Patients

Kultigin Turkmen1, Levent Demirtas, Ergun Topal

  • 1Konya Necmettin Erbakan University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Meram Training and Research Hospital, Konya, Turkey.

Insights

Increased left intra-atrial electromechanical delay (LIAT) and inflammation predict cardiovascular events in hemodialysis (HD) patients. These factors are linked to a higher risk of mortality over two years.

Area of Science:

  • Cardiology
  • Nephrology
  • Biomedical Engineering

Background:

  • Atrial electromechanical delay (AEMD) is a known predictor of cardiovascular morbidity.
  • Evaluating AEMD and other risk factors in hemodialysis (HD) patients is crucial for understanding cardiovascular event risks.

Purpose of the Study:

  • To assess atrial electromechanical delay (AEMD) and other risk factors for 2-year combined cardiovascular (CV) events in hemodialysis (HD) patients.
  • To identify independent predictors of CV events and mortality in this high-risk population.

Main Methods:

  • Prospective study involving 60 HD patients and 44 healthy controls.
  • Echocardiography used to measure AEMD; data analyzed using Spearman test, Kaplan-Meier method, and multivariate Cox regression.
  • Risk factors including C-reactive protein (CRP), albumin, cholesterol, and triglyceride levels were evaluated.

Main Results:

  • HD patients exhibited longer left intra-atrial AEMD times compared to controls.
  • Increased C-reactive protein (CRP) and higher left intra-atrial EMD time (LIAT) were identified as independent predictors of combined CV events.
  • Lower albumin, cholesterol, and triglyceride levels, along with higher CRP and LIAT, were associated with increased all-cause mortality.

Conclusions:

  • Increased left intra-atrial EMD time (LIAT) and inflammation are significantly associated with 2-year combined CV events and all-cause mortality in HD patients.
  • These findings highlight the importance of monitoring AEMD and inflammatory markers in HD patients for risk stratification.
Abstract